AstraZeneca Pharma India Limited receives marketing authorization from DCGI for Fasenra™

AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™).

Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab (Fasenra™) in India, subject to the receipt of related statutory approvals and licenses.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.4343.1 as compared to the previous close of Rs. 4399.5. The total number of shares traded during the day was 2190 in over 490 trades.

The stock hit an intraday high of Rs. 4404 and intraday low of 4335. The net turnover during the day was Rs. 9548706.

Source : Equity Bulls

Keywords